MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
Aurora Cannabis Market Cap 2011-2026 | ACB
As of April 07, 2026 Aurora Cannabis has a market cap of $ 86.3 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aurora Cannabis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 915 M | 804 M | 2.19 B | 2.38 B | 602 M | 44.4 M | 16.9 M | 7.27 M | 480 K | 1.27 M | 25.9 M |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 B | 480 K | 636 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.58 | 1.98 % | $ 1.37 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 19.26 | 0.26 % | $ 123 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.41 | 1.12 % | $ 1.97 B | Canada |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.38 | - | $ 402 M | Canada |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.02 | 2.0 % | $ 110 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.1 | -2.21 % | $ 43.6 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evolus
EOLS
|
271 M | $ 4.16 | 3.23 % | $ 268 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.1 | -1.58 % | $ 415 M | USA |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 35.13 | -0.51 % | $ 1.29 B | USA |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.24 | - | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.27 | -1.89 % | $ 1.03 B | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.34 | -1.47 % | $ 3.37 M | Canada |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 6.9 | -1.29 % | $ 272 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 0.96 | 0.84 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.92 | 3.28 % | $ 45.9 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 7.74 | 3.34 % | $ 677 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.33 | -1.9 % | $ 2.89 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.66 | 1.68 % | $ 4.12 B | Canada |
 |
Veru
VERU
|
108 M | $ 2.4 | 4.8 % | $ 324 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 13.41 | -0.22 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.73 | -0.4 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.61 | -2.94 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.2 | 10.0 % | $ 25.5 M | USA |